Stanford University School of Medicine researchers announced the need for additional participants to complete the first study of a new vaccine against malaria. The NIH-funded Phase-1 clinical trial, underway at both Stanford and Vanderbilt University, “aims to test the safety of and immune response to different doses of the vaccine in a total of 72 healthy adults.”  Results from this study will allow a second trial to begin in Africa this year. Cornelia Dekker, MD, medical director of the Stanford-Lucile Packard Children’s Hospital Vaccine Program, said, “This a chance for those who know that malaria causes millions of deaths every year to step forward and help in the search for preventive vaccine. It’s through the testing of promising vaccine candidates that we may find out how to eradicate malaria.” The Stanford/Packard study “is looking to enroll healthy adults, ages 18 to 45. Over a 12-month period, participants will make 17 clinic visits to Stanford Hospital and will receive three injections into the upper arm muscle of either the vaccine or a placebo. Participants will receive $30 reimbursement for each non-vaccination clinic visit and $60 for each vaccination visit.” http://vaccines.stanford.edu/clinical_trials.html.